Features of the immune response formation to SARS-CoV-2 in patients who have recovered from COVID-19
Keywords:coronavirus disease, COVID-19, antibodies, immunoglobulins, immune response
This study was conducted to assess the presence of an immune response in staff of DILA Medical Laboratory who have recovered from COVID-19, to study the features of monitoring indicators in different clinical variants of the disease. The obtained results allowed analyzing various types of the immune response in patients with a new coronavirus disease. In staff who has recovered from COVID-19, an immune response study was performed by determining the presence of immunoglobulins M and G to various coronavirus target proteins by a semiquantitative method on a chemiluminescence immunoassay analyzer. The findings allowed us to assess not only the intensity of the immune response, but also the relationship with clinical manifestations, disease duration, age, which will be important for further comparative analysis with the immune response of vaccinated employees. The findings showed that most patients with COVID-19 produce protective antibodies, more often to the S-target, and also allowed determining the average duration of circulation of both immunoglobulin M and G antibodies.
Immune Memory after COVID-19 Research yields insights into antibody immunity after infectionBy RACHEL LEESON | Ragon Institute Communications February 17, 2021 ResearchCare Delivery. https://hms.harvard.edu/news/immune-memory-after-covid-19.
Discrete SARS-CoV-2 antibody titers track with functional humoral stability. 15 February 2021. https://www.nature.com/articles/s41467-021-21336-8.
Роббиани Д.Ф. и др. Конвергентные ответы антител на SARS-CoV-2 у выздоравливающих людей. Nature. 2020. 584. 437-442.
Айер А.С. и др. Устойчивость и ослабление ответов человеческих антител на рецептор-связывающий домен спайкового белка SARS-CoV-2 у пациентов с COVID-19. Sci Immunol. 2020. eabe0367.
Tillett R. et al. Геномные доказательства случая повторного заражения SARS-CoV-2 SSRN. 2020.
Лонг Q.X. et al. Ответы антител на SARS-CoV-2 у пациентов с COVID-19. Nat. Med. 2020. 26. 845-848.
Diagnostic testing for SARS-CoV-2: Interim Guidance, 11 September 2020. https://apps.who.int/iris/bitstream/handle/10665/334254/WHO-2019-nCoV-laboratory-2020.6-rus.pdf.
Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. China CDC Weekly. 2020. 2(8). 113-122.
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. 2020 Aug. 26(8). 1200-1204. https://pubmed.ncbi.nlm.nih.gov/32555424. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020 Oct 21. 15(10). e0241104. https://pubmed.ncbi.nlm.nih.gov/33085715. doi: 10.1371/journal.pone.0241104. eCollection 2020.
Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK2021 Apr 27. 8. 642723. doi: 10.3389/fmed.2021.642723. eCollection 2021. https://pubmed.ncbi.nlm.nih.gov/33987193.
SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. 2021 Feb 24. 223(4). 589-599. https://pubmed.ncbi.nlm.nih.gov/33247924. doi:10.1093/infdis/jiaa737.
Hopkins C. Loss of sense of smell as marker of COVID-19 infection. https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf.
Клиническое исследование препаратов для лечения COVID-19 «Solidarity». https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.
Post-COVID Conditions Updated Apr. 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.